Lung Adenocarcinoma Gene Expression Programs for Recurrence Risk Stratification

An Excel spreadsheet containing gene expression analysis results for early-stage lung adenocarcinoma (LUAD). The data was reanalyzed from 292 patient samples in NCBI GEO datasets and validated in a TCGA cohort of 90 patients. It was authored by Jyothi Thyagabhavan Mony and last updated on 2026-04 16.

Use Cases

• Training classifiers to predict recurrence risk based on immune and extracellular matrix gene expression signatures.
• Identifying potential therapeutic targets by analyzing pathways associated with poor prognosis.
• Validating prognostic biomarkers for early-stage lung adenocarcinoma in independent cohorts.
• Exploring the biological dichotomy between protective immune programs and risk-associated ECM remodeling.

Strengths

• Analysis is validated in an independent TCGA cohort of 90 patients.
• Data is derived from a reanalysis of 292 patient samples from NCBI GEO.
• The study integrates immune, tumor, and stromal transcriptional programs.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 547.3 KB file size suggests a limited scope, likely containing summary results rather than raw expression data.

Provenance

Source

figshare, author Jyothi Thyagabhavan Mony.

Collection Method

Reanalysis of gene expression data from NCBI GEO datasets.

Time Range

null

Freshness

Last updated 2026-04-16 05:25:57.

Geography

null